Continuous bioprocessing: A ‘life changing’ method, says NIBRT
On a site visit last month at Ireland’s National Institute for Bioprocessing Research and Technology (NIBRT) in Dublin, Milne told Biopharma-Reporter the continuous method – as opposed to batch – is attracting increased interest in the biologics space.
“In the small molecule industry for example, people have been applying these strategies.
“Biologics has taken a longer time to be convinced,” said Milne, but added he has observed a lot of activity in continuous manufacturing, and will “definitely see more.”
“It is going to change our lives in a very positive way going forward.”
Speaking to delegates at the Biopharma Ambition Conference – also in Dublin – CEO Dominic Carolan said the bioprocessing method has not been taken onboard by all firms.
“Some companies are certainly looking at it closely, some companies have decided perhaps it’s not for them at this point.
“The technologies need to be developed, because this has huge potential of course for reducing cost in the future,” he added.
Continuous bioprocessing training is gaining traction, as demonstrated by Pall Life Sciences announcement last year to equip a Swiss training facility in order to theoretical and practical training in the continuous method to biomanufacturers.
